Oil prices rise on talk of Russia sanctions; bouncing off recent lows
Investing.com - Guggenheim has raised its price target on Regeneron Pharmaceuticals (NASDAQ:REGN) to $815 from $810 while maintaining a Buy rating following the company’s second-quarter results that exceeded investor expectations. According to InvestingPro data, 10 analysts have recently revised their earnings estimates upward, with the stock currently trading at $565.22 and showing a moderate P/E ratio of 13.6x.
The pharmaceutical company reported better-than-anticipated performance driven primarily by strong Dupixent sales and a resilient showing from its Eylea franchise, which has faced competitive pressures and regulatory setbacks. Eylea HD showed a 16% quarter-over-quarter increase in unit demand, while Eylea 2mg experienced a 10% quarter-over-quarter decline. With a market capitalization of $58.6 billion and trailing twelve-month revenue of $14.2 billion, Regeneron maintains a strong financial position, earning a "GOOD" overall health score from InvestingPro.
Regeneron expects continued erosion for Eylea 2mg in the second half of 2025, projecting approximately 10% quarter-over-quarter unit demand decline, while Eylea HD demand is anticipated to remain stable. The company also disclosed that August PDUFA dates for Eylea HD will be delayed due to ongoing site inspection issues, with Novo planning to submit FDA responses next week.
Dupixent sales exceeded estimates as launches in COPD and newly approved indications for CSU and BP (NYSE:BP) gain momentum. Libtayo has grown 25% year-over-year, now generating annual sales exceeding $1 billion, and remains the leading anti-PD1 treatment in advanced CSCC and BCC melanomas.
Regeneron management indicated a potential shift in business development strategy, showing openness to "considering differentiated later stage opportunities in areas with high unmet medical need" compared to its previous focus on early-stage assets and platform technologies, with pivotal Phase III data for pozelimab+cemdisiran in gMG expected in the third quarter of 2025. For deeper insights into Regeneron’s strategic positioning and comprehensive financial analysis, access the detailed Pro Research Report available exclusively on InvestingPro, which covers over 1,400 top US stocks.
In other recent news, Regeneron Pharmaceuticals reported impressive financial results for the second quarter of 2025. The company’s earnings per share (EPS) soared to $12.89, significantly beating the expected $8.50, marking an increase of 51.65%. Revenue also surpassed projections, reaching $3.68 billion compared to the anticipated $3.29 billion. Bernstein SocGen Group responded by raising its price target for Regeneron to $753, citing strong earnings despite some regulatory challenges. Additionally, RBC Capital increased its price target to $695, highlighting strong growth in Dupixent and resilience from Eylea. BMO Capital also raised its price target to $640, noting a "much-needed clean quarter" for the company. Leerink Partners maintained its Outperform rating, projecting a 7% compound annual growth rate in revenue from 2025 to 2030. The firm also noted management’s plans for a head-to-head trial for Lynozyfic in multiple myeloma. These developments reflect a positive outlook from analysts and strong performance across Regeneron’s major products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.